EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1 , 1B and 2A

Carolynne M Doherty iD, Jasper M Morrow iD, Riccardo Zuccarino, Paige Howard, Stephen Wastling, Menelaos Pipis, Nick Zafeiropoulos, Katherine J Stephens, Tiffany Grider, Shawna M E Feely, Peggy Nopoulous, Mariola Skorupinska und 14 weitere

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.51979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Carolynne M Doherty und 25 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK. Hauptthemen laut MEDLINE: Charcot-Marie-Tooth Disease. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Muscular Dystrophy Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

With potential therapies for many forms of Charcot‐Marie‐Tooth disease (CMT), responsive outcome measures are urgently needed for clinical trials. Quantitative lower limb MRI demonstrated progressive calf intramuscular fat accumulation in the commonest form, CMT1A with large responsiveness. In this study, we evaluated the responsiveness and validity in the three other common forms, due to variants in GJB1 (CMTX1), MPZ (CMT1B) and MFN2 (CMT2A).

Methods

22 CMTX1, 21 CMT1B and 21 CMT2A patients and matched controls were assessed at a 1‐year interval. Intramuscular fat fraction (FF) was evaluated using three‐point Dixon MRI at thigh and calf level along with clinical measures including CMT examination score, clinical strength assessment, CMT‐HI and plasma neurofilament light chain.

Results

All patient groups had elevated muscle fat fraction at thigh and calf levels, with highest thigh FF and atrophy in CMT2A. There was moderate correlation between calf muscle FF and clinical measures (CMTESv2 rho = 0.405; p = 0.001, ankle MRC strength rho = −0.481; p < 0.001). Significant annualised progression in calf muscle FF was seen in all patient groups (CMTX1 2.0 ± 2.0%, p < 0.001, CMT1B 1.6 ± 2.1% p = 0.004 and CMT2A 1.6 ± 2.1% p = 0.002). Greatest increase was seen in patients with 10–70% FF at baseline (calf 2.7 ± 2.3%, p < 0.0001 and thigh 1.7 ± 2.1%, p = 0.01).

Interpretation

Our results confirm that calf muscle FF is highly responsive over 12 months in three additional common forms of CMT which together with CMT1A account for 90% of genetically confirmed cases. Calf muscle MRI FF should be a valuable outcome measure in upcoming CMT clinical trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Charcot-Marie-Tooth DiseaseHumansMuscle, SkeletalLower ExtremityMagnetic Resonance ImagingOutcome Assessment, Health Care

Autor:innen und Institutionen

  • Centre for Neuromuscular Diseases, Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, London, UK.
  • Roy and Lucille Carver College of Medicine, University of Iowa, Iowa City, Iowa, USA.
  • Fondazione Serena Onlus, Centro Clinico NeMO Trento, Pergine Valsugana, Italy.
  • Lysholm Department of Radiology, National Hospital for Neurology and Neurosurgery, London, UK.
  • Seattle Children's Hospital, University of Washington School of Medicine, Seattle, Washington, USA.
  • Great Ormond Street Hospital, London, UK.

ORCID-Profile: Carolynne M Doherty, Jasper M Morrow, Alexander M Rossor, Michael E Shy

Förderung

  • Muscular Dystrophy Association

Zitieren

APA

Doherty, C. M., Morrow, J. M., Zuccarino, R., Howard, P., Wastling, S., Pipis, M., Zafeiropoulos, N., Stephens, K. J., Grider, T., Feely, S. M. E., Nopoulous, P., Skorupinska, M., Milev, E., Nicolaisen, E., Dudzeic, M., McDowell, A., Dilek, N., Muntoni, F., Rossor, A. M., …, & Reilly, M. M. (2024). Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1 , 1B and 2A. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.51979

Vancouver

Doherty CM, Morrow JM, Zuccarino R, Howard P, Wastling S, Pipis M, et al. Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1 , 1B and 2A. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.51979

BibTeX
@article{Doherty2024,
  author = {Doherty, Carolynne M and Morrow, Jasper M and Zuccarino, Riccardo and Howard, Paige and Wastling, Stephen and Pipis, Menelaos and Zafeiropoulos, Nick and Stephens, Katherine J and Grider, Tiffany and Feely, Shawna M E and Nopoulous, Peggy and Skorupinska, Mariola and Milev, Evelin and Nicolaisen, Emma and Dudzeic, Magdalena and McDowell, Amy and Dilek, Nuran and Muntoni, Francesco and Rossor, Alexander M and Shah, Sachit and Laura, Matilde and Yousry, Tarek A and Thedens, Daniel and Thornton, John and Shy, Michael E and Reilly, Mary M},
  title = {Lower limb muscle MRI fat fraction is a responsive outcome measure in CMT X1 , 1B and 2A},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.51979}
}
Kostenlos starten →